CD38作为瘤学中的治疗目标
Valentina Bocuzzi1,2, Jessica Bridoux3, Michelle Pirotte4
1Laboratory of Hematology, GIGA I3, University of Liège, Liège, Belgium.
Journal of translational medicine
|November 5, 2024
概括
向CD38,一种在血液癌症中过度表达的蛋白质,对于治疗至关重要. 单域抗体 (sdAbs) 为表达CD38的恶性瘤提供了一种新的治疗方法,结合了诊断和治疗.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 核医学就是核医学.
背景情况:
- CD38是一种跨膜糖蛋白,在白血病和多发性髓瘤 (MM) 等血液性恶性瘤中过度表达.
- 它通过ADP-ribosylcyclase和cADPR-hydrolase活动在疾病进展中发挥关键作用.
- 目前的抗CD38单克隆抗体 (mAbs) 显示出有效性,但面临耐药性,需要新的治疗策略.
研究的目的:
- 审查CD38作为瘤学点的作用.
- 探索单域抗体 (sdAbs) 作为CD38表达癌症的创新治疗剂.
主要方法:
- 关于瘤学中CD38向的当前文献的综述.
- 讨论诊断 (PET/SPECT) 和治疗 (α/β发射放射性核素) 放射性体疗法 (RLT) 的方法.
- 描述CD38特定的sdAbs及其工程构造用于theranostic应用.
主要成果:
- CD38向是血液恶性瘤中验证的策略,在固体瘤中显示出潜力.
- 像达拉图穆马布这样的抗CD38mAbs改善了MM治疗结果.
- 单域抗体 (sdAbs) 在尺寸,稳定性和表位体识别方面具有优势,可用于神经发育.
结论:
- CD38仍然是瘤学中重要的治疗点.
- 单域抗体 (sdAbs) 是一种有前途的新一代治疗CD38表达性恶性瘤的治疗药物.
- 设计的sdAbs提供了增强的瘤向和结合诊断和治疗应用的潜力.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K